{"id":25040,"date":"2025-12-05T20:03:33","date_gmt":"2025-12-05T12:03:33","guid":{"rendered":"https:\/\/www.hkioc.com.hk\/?p=25040"},"modified":"2025-12-08T14:12:40","modified_gmt":"2025-12-08T06:12:40","slug":"%e5%b8%95%e5%8d%9a%e5%88%a9%e7%8f%a0%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88enfortumab-vedotin%e8%8e%b7fda%e6%89%b9%e5%87%86%ef%bc%8c%e4%b8%ba%e8%82%8c%e5%b1%82%e6%b5%b8%e6%b6%a6%e6%80%a7%e8%86%80","status":"publish","type":"post","link":"https:\/\/www.hkioc.com.hk\/zh-hans\/%e5%b8%95%e5%8d%9a%e5%88%a9%e7%8f%a0%e5%8d%95%e6%8a%97%e8%81%94%e5%90%88enfortumab-vedotin%e8%8e%b7fda%e6%89%b9%e5%87%86%ef%bc%8c%e4%b8%ba%e8%82%8c%e5%b1%82%e6%b5%b8%e6%b6%a6%e6%80%a7%e8%86%80\/","title":{"rendered":"\u5e15\u535a\u5229\u73e0\u5355\u6297\u8054\u5408Enfortumab vedotin\u83b7FDA\u6279\u51c6\uff0c\u4e3a\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\u60a3\u8005\u63d0\u4f9b\u65b0\u9009\u62e9"},"content":{"rendered":"\n

2025\u5e7411\u670821\u65e5\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6PD-1\u6291\u5236\u5242\u5e15\u535a\u5229\u73e0\u5355\u6297\uff08Pembrolizumab\uff09\u4e0e\u6297\u4f53\u5076\u8054\u836f\u7269\uff08ADC\uff09Enfortumab vedotin\u8054\u5408\uff0c\u7528\u4e8e\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08MIBC\uff09\u6210\u5e74\u60a3\u8005\u7684\u672f\u524d\uff08\u65b0\u8f85\u52a9\uff09\u6cbb\u7597\uff0c\u5e76\u5728\u8180\u80f1\u5207\u9664\u672f\u540e\u7ee7\u7eed\u4f5c\u4e3a\u672f\u540e\uff08\u8f85\u52a9\uff09\u6cbb\u7597\uff0c\u9002\u7528\u4e8e\u4e0d\u7b26\u5408\u987a\u94c2\u5316\u7597\u6cbb\u7597\u6761\u4ef6\u7684\u60a3\u8005\u3002<\/p>\n\n\n\n

\u6279\u51c6\u4f9d\u636e<\/strong><\/strong><\/p>\n\n\n\n

\u6b64\u6b21\u6279\u51c6\u57fa\u4e8e3\u671fKEYNOTE-905\/EV-303\u8bd5\u9a8c\u7684\u7ed3\u679c\u3002
\u8bd5\u9a8c\u4e2d\u5171\u7eb3\u5165344\u4f8b\u65e2\u5f80\u672a\u63a5\u53d7\u6cbb\u7597\u7684\u808c\u5c42\u6d78\u6da6\u6027\u8180\u80f1\u764c\uff08Muscle-Invasive Bladder Cancer\uff0cMIBC\uff09\u60a3\u8005\uff0c\u8fd9\u4e9b\u60a3\u8005\u7b26\u5408\u6839\u6cbb\u6027\u8180\u80f1\u5207\u9664\uff08Radical Cystectomy\uff0cRC\uff09\u8054\u5408\u76c6\u8154\u6dcb\u5df4\u7ed3\u6e05\u626b\uff08Pelvic Lymph Node Dissection\uff0cPLND\uff09\u6307\u5f81\uff0c\u4f46\u4e0d\u7b26\u5408\u6216\u62d2\u7edd\u987a\u94c2\u5316\u7597\u3002
\u60a3\u8005\u88ab\u63091:1\u968f\u673a\u5206\u7ec4\uff1a\u4e00\u7ec4\u63a5\u53d7\u672f\u524dPembrolizumab\u8054\u5408Enfortumab vedotin\u6cbb\u7597\uff0c\u968f\u540e\u624b\u672f\uff0c\u7136\u540e\u63a5\u53d7\u672f\u540ePembrolizumab\u8054\u5408Enfortumab vedotin\u6cbb\u7597\uff0c\u5e76\u6700\u7ec8\u4ee5Pembrolizumab\u5355\u836f\u7ef4\u6301\u6cbb\u7597\uff1b\u53e6\u4e00\u7ec4\u5219\u76f4\u63a5\u8fdb\u884c\u624b\u672f\u3002
\u8bd5\u9a8c\u7684\u4e3b\u8981\u7597\u6548\u7ec8\u70b9\u4e3a\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002\u6b21\u8981\u7ec8\u70b9\u4e3a\u603b\u751f\u5b58\u671f\uff08OS\uff09\u3002
\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u662f\u6307\u60a3\u8005\u4ece\u63a5\u53d7\u6cbb\u7597\u5f00\u59cb\uff0c\u5230\u51fa\u73b0\u75be\u75c5\u8fdb\u5c55\u3001\u590d\u53d1\u3001\u6b7b\u4ea1\u6216\u5176\u4ed6\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u4e2d\u7684\u4efb\u4e00\u60c5\u51b5\u4e3a\u6b62\u7684\u65f6\u95f4\u3002<\/p>\n\n\n\n

\u7814\u7a76\u7ed3\u679c<\/strong><\/strong><\/p>\n\n\n\n

\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff0c\u4e0e\u5355\u7eaf\u624b\u672f\u76f8\u6bd4\uff0c\u5728\u624b\u672f\u524d\u540e\u4f7f\u7528Pembrolizumab\u8054\u5408Enfortumab vedotin\u6cbb\u7597\u7684\u60a3\u8005\uff0c\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u548c\u603b\u751f\u5b58\u671f\uff08OS\uff09\u5747\u6709\u663e\u8457\u6539\u5584\u3002
\u8054\u5408\u6cbb\u7597\u7ec4\u7684\u5e73\u5747\u65e0\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u5c1a\u672a\u8fbe\u5230\uff08NR\uff09<\/strong>\uff0c\u5373\u5728\u7814\u7a76\u7ed3\u675f\u65f6\u5927\u591a\u6570\u60a3\u8005\u8fd8\u6ca1\u590d\u53d1\u6216\u8fdb\u5c55\uff1b\u800c\u624b\u672f\u7ec4\u4e3a15.7\u4e2a\u6708<\/strong>\uff0c\u5373\u5927\u90e8\u5206\u60a3\u8005\u572815.7\u4e2a\u6708\u5185\u51fa\u73b0\u4e86\u590d\u53d1\u6216\u8fdb\u5c55\u3002
\u8054\u5408\u6cbb\u7597\u7ec4\u7684\u5e73\u5747\u603b\u751f\u5b58\u671f\uff08OS\uff09\u5c1a\u672a\u8fbe\u5230\uff08NR\uff09<\/strong>\uff0c\u5373\u5728\u7814\u7a76\u7ed3\u675f\u65f6\u5927\u591a\u6570\u60a3\u8005\u4ecd\u7136\u5b58\u6d3b\uff1b\u800c\u624b\u672f\u7ec4\u4e3a41.7\u4e2a\u6708<\/strong>\uff0c\u5373\u5927\u90e8\u5206\u60a3\u8005\u80fd\u5b58\u6d3b41.7\u4e2a\u6708\u3002<\/p>\n\n\n\n

\u5b89\u5168\u6027<\/strong><\/strong><\/p>\n\n\n\n

Pembrolizumab\u8054\u5408Enfortumab vedotin\u6cbb\u7597\u7684\u603b\u4f53\u5b89\u5168\u6027\u4e0e\u5176\u5728\u65e2\u5f80\u665a\u671f\u5c3f\u8def\u4e0a\u76ae\u764c\u7814\u7a76\u4e2d\u7684\u8868\u73b0\u4e00\u81f4\u3002
Pembrolizumab\u7684\u8bf4\u660e\u4e66\u4e2d\u5305\u62ec\u4ee5\u4e0b\u526f\u4f5c\u7528\uff1a\u514d\u75ab\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\u3001\u8f93\u6ce8\u76f8\u5173\u53cd\u5e94\u3001\u5f02\u57fa\u56e0\u9020\u8840\u5e72\u7ec6\u80de\u79fb\u690d\u540e\u7684\u5e76\u53d1\u75c7\uff0c\u4ee5\u53ca\u80da\u80ce-\u80ce\u513f\u6bd2\u6027\u7b49\u8b66\u544a\u3002
Enfortumab vedotin\u7684\u8bf4\u660e\u4e66\u4e2d\u5305\u62ec\u4ee5\u4e0b\u526f\u4f5c\u7528\uff1a\u76ae\u80a4\u53cd\u5e94\u3001\u9ad8\u8840\u7cd6\u3001\u80ba\u708e\/\u95f4\u8d28\u6027\u80ba\u75c5\uff08Interstitial Lung Disease,\u00a0ILD\uff09\u3001\u5468\u56f4\u795e\u7ecf\u75c5\u53d8\u3001\u773c\u90e8\u95ee\u9898\u3001\u8f93\u6ce8\u90e8\u4f4d\u6e17\u6f0f\uff0c\u4ee5\u53ca\u80da\u80ce-\u80ce\u513f\u6bd2\u6027\u7b49\u8b66\u544a\u3002<\/p>\n\n\n\n

\u5b89\u5168\u6027\u6570\u636e\u663e\u793a\uff1a<\/strong><\/p>\n\n\n\n

\u2022\u00a0\u8054\u5408\u6cbb\u7597\u7ec4\u6709100%\u7684\u60a3\u8005\u51fa\u73b0\u4e86\u4efb\u610f\u7ea7\u522b\u7684\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u624b\u672f\u7ec4\u4e3a64.8%<\/strong>\u3002
\u2022\u00a0\u8054\u5408\u6cbb\u7597\u7ec4\u670971.3%\u7684\u60a3\u8005\u51fa\u73b0\u4e86\u4e25\u91cd\u76843\u7ea7\u6216\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u624b\u672f\u7ec4\u4e3a45.9%<\/strong>\u3002
\u2022\u00a0\u8054\u5408\u6cbb\u7597\u7ec4\u670958.1%\u7684\u60a3\u8005\u51fa\u73b0\u4e86\u4e25\u91cd\u7684\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\uff0c\u624b\u672f\u7ec4\u4e3a40.9%<\/strong>\u3002
\u2022\u00a0\u8054\u5408\u6cbb\u7597\u7ec4\u67094.0%\u7684\u60a3\u8005\u624b\u672f\u5ef6\u8fdf\uff0c\u624b\u672f\u7ec4\u4e3a0.6%<\/strong>\u3002
\u2022\u00a0Enfortumab vedotin\u7684\u5242\u91cf\u4e0b\u8c03\u53d1\u751f\u7387\u4e3a16.8%\uff0c\u505c\u7528\u7387\u4e3a41.3%\uff1bPembrolizumab\u7684\u505c\u7528\u7387\u4e3a34.1%\u3002
\u2022\u00a0\u4e0e\u6cbb\u7597\u76f8\u5173\u5bfc\u81f4\u6b7b\u4ea1\u7684\u4e0d\u826f\u4e8b\u4ef6\u53d1\u751f\u7387\uff1a\u8054\u5408\u6cbb\u7597\u7ec4\u4e3a7.8%\uff0c\u624b\u672f\u7ec4\u4e3a5.7%<\/strong>\u3002<\/p>\n\n\n\n

\u8d44\u6599\u6765\u6e90\uff1a<\/p>\n\n\n\n

[1]https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
[2]https:\/\/www.onclive.com\/view\/fda-approves-perioperative-enfortumab-vedotin-plus-pembrolizumab-for-cisplatin-ineligible-mibc<\/p>\n\n\n\n

\u8f6c\u8f7d\u8bf7\u8054\u7cfb\u6388\u6743\uff0c\u6216\u6ce8\u660e\u6765\u6e90\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

2025\u5e7411\u670821\u65e5\uff0c\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6PD-1\u6291\u5236\u5242\u5e15\u535a\u5229\u73e0\u5355\u6297\uff08Pembrolizum<\/p>\n","protected":false},"author":14,"featured_media":25032,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1769,6646],"tags":[],"yst_prominent_words":[],"class_list":["post-25040","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-treatment-zh-hans","category-6646"],"_links":{"self":[{"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/25040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/comments?post=25040"}],"version-history":[{"count":3,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/25040\/revisions"}],"predecessor-version":[{"id":25055,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/posts\/25040\/revisions\/25055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/media\/25032"}],"wp:attachment":[{"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/media?parent=25040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/categories?post=25040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/tags?post=25040"},{"taxonomy":"yst_prominent_words","embeddable":true,"href":"https:\/\/www.hkioc.com.hk\/zh-hans\/wp-json\/wp\/v2\/yst_prominent_words?post=25040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}